Development of modified microRNA therapeutics

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$287,270.00
Award Year:
2010
Program:
SBIR
Phase:
Phase I
Contract:
1R43CA153876-01
Award Id:
95943
Agency Tracking Number:
CA153876
Solicitation Year:
n/a
Solicitation Topic Code:
NCI
Solicitation Number:
n/a
Small Business Information
MIRNA THERAPEUTICS, INC., 2150 WOODWARD ST, AUSTIN, TX, 78744
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
805509424
Principal Investigator:
DAVID BROWN
() -
DBROWN@MIRNARX.COM
Business Contact:
TODD PAPPAS
() -
bandruss@mirnarx.com
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): Experimental evidence accumulated in the past few years indicates that several miRNAs likely function as tumor suppressors and that the altered expression of these miRNAs likely contributes to a significant number of hu man cancers. Mirna Therapeutics has identified approximately ten tumor suppressor miRNAs and is in the process of developing mimetics for two of these that will be subjected to efficacy and safety studies using advanced rodent and primate studies. These st udies will ultimately be used to support an IND submission to the FDA for one or more miRNA-based therapies for the treatment of cancer patients. The focus of our proposed Phase I research is to use nucleotide analogs to improve the stabilities and activit ies of mimetics of two miRNAs that have proven to have therapeutic activities in mouse models of several different cancers. The goal for Phase I of the project is to create mimetics that are as much as ten-fold more effective than our current unmodified mi metics in inhibiting tumor growth in mice. Modified mimetics developed during Phase I will support our Phase II effort wherein the mimetics will be coupled with delivery agents developed in a parallel program. The mimetic/delivery combinations will be eval uated for therapeutic activities and pharmacokinetics using mouse models. The Specific Aims for our Phase I research are: (1) Develop modified mimetics with favorable stabilities and equivalent activities to unmodified mimetics and (2) Verify that the modi fied mimetics have therapeutic activities and target specificities that are equivalent to the unmodified miRNA mimetics that we have used for our efficacy studies to date. PUBLIC HEALTH RELEVANCE: Statement of Clinical Relevance Targeted therapies h ave the potential to revolutionize the treatment of cancer patients. A number of naturally occurring microRNAs, a newly discovered class of genetically-encoded RNA molecules, appear to function as powerful tumor suppressors in humans. We are developing syn thetic versions of two of the more powerful tumor suppressor miRNAs to create therapies that can be used to inhibit the progression of cancer.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government